We don't recommend buying stock in Teva Pharmaceutical, but there's a way to profit from Teva even if its share price doesn’t move. Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and serves as Director of the Investing Daily Wealth Society. He is also the Director of Research at Investing Daily, overseeing the work of our entire analyst team. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms and investment advisors. Jim has a BA in Business Management from The College of William & Mary, and a CFP from the College for Financial Planning.
Analyst Articles
Due to an accounting blunder, NV5 misstated earnings guidance for next year and its stock tanked. Here's how our expert plans to cash in. Read More
Someone loaded up on NXTC fast. Whoever made the trade may get an unfriendly visit from the SEC. Read More
After releasing better than expected Q3 results on October 30, General Electric is up nearly 20%. Read More
This India-based vehicle maker faces complex conditions, but here's a way to leverage these movements for market-beating profits. Read More
It never hurts to negotiate in good faith, but it would be a mistake for Tiffany to take a hostile stance towards this deal. Read More
Nokia lost nearly a quarter of its value after reducing guidance, so now may be the time to make this trade. Read More
The optimism that propelled pot stocks last year could pale to the euphoria that may drive some of them to future heights. Read More
This trade more than tripled the S&P 500's 2.4 % gain even though the underlying share price did worse than the index! Read More
The sudden interest in timeshare operator Hilton Grand Vacations underscores the appeal of real estate in a frothy equity market. Read More